Fosun Pharma (02196.HK) subsidiary Fosun Antech intends to increase capital and expand its shares.

Wisdom Financial News APP, Fosun Pharma (02196.HK) announced that on June 15, 2026, its subsidiary Fosun Anticorrosive Antimicrobial signed a Subscription Agreement and Shareholders' Agreement with four investors, in which Fosun Anticorrosive Antimicrobial plans to issue a total of 11.4954 million shares at a price of 84.207235 yuan per share to these investors (approximately 12.15% of the total number of shares of the target company after this capital increase and expansion). Among them, external investors plan to subscribe for a total of 418 million yuan for 4.9639 million shares, and the company's controlling subsidiary, Fosun Pharmaceutical Industry (the direct controlling shareholder of Fosun Anticorrosive Antimicrobial), plans to subscribe for 553 million yuan for 6.5315 million shares.